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There is evidence that the active form of vitamin D, 1,25 dihydroxyvitamin D 
(1,25(OH)2D), may lead to reduced tumor formation by inhibiting vascularization, and thus 
feeding the tumor (1).  Vascularization is controlled in part by the release of proteins which can 
be stimulated by low oxygen (hypoxia) to increase the transcriptional activity of hypoxia 
inducible factor 1α (HIF-1α) (2).  HIF-1α controls the level of an important protein, vascular 
endothelial growth factor (VEGF), which stimulates vascularization (2). The level of HIF-1α 
protein level is regulated both transcriptionally and by protein stability through the activity of 
prolyl hydroxylase (PHD) (2).  The purpose of this study is to determine if 1,25(OH)2D alters the 
mRNA expression of  HIF-1α in untransformed (normal) cells and cells that contain the ErbB2 
oncogene, a mutated gene commonly found in cancers. 
Literature Review 
Breast cancer is the most prevalent cancer affecting women. Around the globe each year 
there are approximately 1,115,000 cases and 410,000 deaths due to breast cancer (3).  In 2006, 
there were 215,000 cases and 41,000 deaths resulting from breast cancer (3).  The estimated 
statistics for diagnosis is 192,370 and 40,170 for deaths in 2009 (4,5).   
Vitamin D can be obtained from the diet or from the sunlight acting on the skin. The 
sunlight acting on the skin is responsible for 90-95% of humans’ vitamin D requirement (6).  
When skin is exposed to sunlight, the UV rays stimulate the photolytic conversion of 7-
dehydrocholesterol to previtamin D3 in the dermis and epidermis.  Previtamin D3 is isomerized 
by body temperature rapidly to vitamin D3 (6).  Once Vitamin D enters the body it is 
hydroxylated on carbon 25, resulting in 25-hydroxyvitmain D (25(OH)D) in the liver. This is the 
major circulating form of vitamin D (6).  The 25-hydroxyvitamin D is then hydroxylated at the 1 
carbon to form 1,25-dihydroxyvatmin D (1,25(OH)2D) in the kidney (7).  This is the biologically 
active form of vitamin D.  This metabolite regulates cellular growth as well as calcium, 
phosphorus, and bone metabolism (6).   
 The relationship of the intake of vitamin D and breast cancer prevention is a well studied 
area.  For example, a study by Knight, et al., showed that there was a reduced risk for breast 
cancer associated with cod liver use and increasing milk consumption, both dietary sources of 
vitamin D (8).  In addition, there was a reduced risk for breast cancer in adulthood associated 
with higher sun exposure from ages 10 to 19 (8).  The researchers stated that exposure earlier in 
life, particularly during breast development, may be a critical period to decrease risk for breast 
cancer development (8).   A study involving postmenopausal women found that the association 
of high vitamin D intake with breast cancer was the strongest in the first 5 years after the dietary 
assessment and then the vitamin D intake declined (9).  The researchers showed that vitamin D 
intake of greater than 800 IU/day was associated with a small decrease in risk (9). 
 Exposure to the sunlight may decrease the risk for breast cancer by increasing the 
production of vitamin D3 in the skin, which would result in a higher circulating level of 
25(OH)D (3, 6, 7, 8).  The 25(OH)D can be metabolized in breast tissue to 1,25(OH)2D which 
may  increases the cellular level of 1,25(OH)2D (6). An increase in 1,25(OH)2D may help 
maintain cellular growth and prevent the cells from becoming malignant (6).   
The vitamin D receptor, VDR, and 1,25(OH)2D affect the proliferation, differentiation 
and apoptosis in mammary glands (10).  Thus, there is a possibility that optimal vitamin D status 
may protect against mammary epithelial cell transformation with ultimate development of 
tumors (10).  Preclinical studies in animals show that vitamin D compounds can reduce breast 
cancer development (10).  There is also human data which show that both vitamin D status and 
genetic variations in the VDR may affect one’s breast cancer risk 10).  Thus, vitamin D may be 
an effective chemopreventive agent against the development of breast cancer; however, it is not 
clear how vitamin D may inhibit tumor development (1).  Mechanisms proposed include the 
regulation of blood vessel supply to the tumor regulated by low oxygen status, or hypoxia. 
Hypoxia is the major pathophysiologic condition that regulates angiogenesis (1). The adaptive 
changes in response to hypoxia can lead toward treatment resistance to both radio and 
chemotherapy (11). Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that is a master 
regulator of oxygen homeostasis and it mediates increased angiogenesis in response to hypoxia 
(2).  It is composed of HIF-1α and HIF-1β.  HIF-1α protein present in the cell regulates the 
formation and transcriptional activity of HIF-1 (2).  The expression of HIF-1α, at least in part, is 
controlled by the cellular oxygen tension.  HIF-1α is very unstable under normoxic condition 
having a half-life of less than 10 minutes (2). HIF-1α protein level is regulated at three levels; 
increase in transcription, mRNA stability and through protein degradation (2).  Protein 
degradation is controlled primarily by prolyl hydroxylase (PHD). PHD hydroxylates HIF-1α and 
thus targets the protein for degradation, reducing the amount of HIF-1α protein (2).  HIF-1 aids 
in tumor cell survival under hypoxic conditions through the expression of gene products that 
promote anaerobic ATP synthesis (glucose transporter, a series of glycolytic enzyme, and cell 
survival factors) (2). HIF-1 also induces the expression of vascular endothelial growth factor 
(VEGF), a critical angiogenic factor which promotes blood vessel formation to supply oxygen 
and nutrients to cells for growth, including tumors (2).  
 There is an increasing amount of evidence that shows that HIF-1 contributes to tumor 
progression and metastasis (2). Studies have shown that the expression levels of HIF-1α in 
biopsies of various tumors correlate with tumor aggressiveness, vascularity, treatment failure, 
and mortality (2). Another study showed similar results finding that high HIF-1α expression was 
associated with poor overall survival and high risk for metastasis (11). One study showed that 
preneoplastic lesions in breast, colon, and prostate overexpressed HIF-1α, but there was no 
increase in benign tumors in the breast and uterus (12).  The same study also showed that HIF-1α 
overexpression was noted in only 29% of primary breast cancers, but was noted in 69% of breast 
cancer metastases (12).  The data from this study suggests that overexpression of HIF-1α can 
occur early in carcinogenesis even before histological evidence of angiogenesis or invasion (12).    
There are multiple steps involved before a tumor develops and becomes metastatic. The 
stages are initiation, promotion, conversion and progression (13).  It is important to study these 
stages because nutritional components may inhibit any of them. Since nutrients are readily 
available and low risk it is likely a good preventative tool.  It is important to study how nutrients 
affect the early stages of ‘normal’ cells, initiation, and promotion to see if it will be effective at 
the later stages, but at the same time not harmful in ‘normal’ cells. The ErbB2 oncogene has 
been associated with larger tumors in a few studies (14). The main mechanism of ErbB2 
acitvation involves amplification.  This has always been associated with overexpression (14).  
The HER2 receptor tyrosine kinase encoded by ErbB2 occurs in approximately 1/3 of breast 
tumors and is associated with increased tumor grade, chemotherapy resistance, and decreased 
rates of patient survival (15). Understanding how vitamin D regulates cellular metabolism in 
cells containing the mutated ErbB2 gene will contribute to identifying if vitamin D will be an 
effective chemopreventive agent in an early stage of cancer development. 
Vascular endothelial growth factor (VEGF) is known as proangiogenic factor (16).  
Angiogenesis is known as the formation of new blood vessels from preexisting vasculature (16).  
Angiogenesis is essential in normal development, growth and maintenance of bone structure, 
reproduction, and wound healing (16). More evidence is starting to show that angiogenesis plays 
an imperative role in the progression of cancer (16).  It is important to study VEGF because HIF-
1α controls the levels of this growth factor (2). Since 1,25(OH)2D affects multiple cellular 
signaling pathways in multiple cell types, it has been hypothesized that it may have an influence 
on angiogenesis (16).  Studies have shown that 1,25(OH)2D influences angiogenesis in a variety 
of target tissues by regulating 1 or more components of the angiogenic process (16).  A study 
was done by Levine and Teegarden investigating the effects of 1,25(OH)2D on angiogenesis in 
normal cells versus cancerous cells (16).  The researchers found evidence that 1,25(OH)2D 
altered the angiogenic phenotype of human umbilical vein endothelial cells after being treated 
with 1,25(OH)2D-treated C3H10T1/2 mouse fibroblasts and their Harvey ras-oncogence 
transfected counterparts (16).  When MCF10A AND MCF10Aras cells (a human breast 
epithelial cell model for multistage carcinogensis) were studied, the researchers found similar 
effects on VEGF release (16).  Other Studies show VEGF is significantly induced after exposure 
to hypoxia due to the increase in HIF-1α (1).  When treated with 1,25(OH)2D, VEGF was 
significantly inhibited under normoxic and hypoxic conditions (1).   
There is evidence that 1,25(OH)2D inhibits HIF-1α expression in tumor cells (17).  
However, it is not known if 1,25(OH)2D has an impact on HIF-1α gene expression in normal or 
in cells which are models for multistage carcinogenesis such as those containing the ErbB2 
oncogene, a common genetic mutation found in breast cancer, under normoxic or hypoxic 
conditions. The purpose of this study is to determine if 1,25(OH)2D alters the mRNA expression 
of  HIF-1α in untransformed (normal) cells and cells that contain the ErbB2 oncogene, a mutated 
gene commonly found in cancers. The hypothesis is that 1,25(OH)2D treatment of normal breast 
cells in a hypoxic environment will increase HIF-1α expression.  In contrast, 1,25(OH)2D 
treatment of ErbB2 oncogene containing cells in a hypoxic condition will decrease the 
expression of HIF-1α.  
Methods 
Human mammary epithelial MCF10A and MCF10A cells transfected with the ErbB2 
oncogene were used in these experiments. The MCF10A cell line is derived from benign, or 
untransformed, breast tissue. This is a good model for normal breast tissue and cancer 
progression. The cells were maintained in MEGM (Mammary Epithelial Growth Medium, 
Serum-free), supplemented with 100 ng/ml cholera toxin and 1% penicillin-strep at 37 C with 
5% CO2.  The cells were treated with the vehicle (ethanol) and 10 nM of 1,25(OH)2D in culture 
medium for 24 hours.  For the hypoxic conditions the cells were treated with 100 uM of cobalt 
chloride 2 hours before harvest.  The RNA was isolated by Trizol as per manufacturer’s 
instructions.  The c-DNA was prepared by using the olgioDT and random hexamer primers using 
the Omniscript kit from Qiagen.  Brilliant SYBR green QPCR Master Mix (Stratagene, Cedar 
Creek, TX) in at least duplicate using a thermocycler (Mx3000P, Stratagene) was used to check 
for gene expression.  The final n minimum for each point was 6.  Gene expression levels were 




 VEGF: CAAGATCCGCAGACGTGTAA 
  TCACATCTGCAAGTACGTTCG 
  
 HIF-1a: TGCTGAAGACACAGAAGCAAA 
    AAAGCGAAGTCCTCAAAGC 
  
 PHD:  CTTTGACCGGTTGCTCATTT 
  TAGGCGGCTGTGATACAGGT 
 
 GAPDH: TCACCATCTTCCAGGAGCG 
     CTGCTTCACCACCTTCTTGA 
 
Statistical Analysis  
 
 Statistical analysis was determined by using ANOVA. A p value of less than 0.05 was 

























To determine if 1,25(OH)2D regulates HIF-1α mRNA expression, untransformed and 
ErbB2 containing cells were treated with vehicle or 1,25(OH)2D for 24 hours and mRNA levels 
determined.  1,25(OH)2D significantly reduced HIF-1α mRNA abundance in both cell lines 
under normoxic conditions but not under hypoxic conditions (Figure 1).  
 
 
Figure 1: Effects of 1,25(OH)2D on the 
expression of HIF-1a under normal and 
hypoxic conditions. Cells were treated for 24 
hours with vehicle of 1,25(OH)2D, and cells 
harvested for determination of HIF-1α mRNA 
abundance using RT-PCR.  Bars with different 















The effect of 1,25(OH)2D on PHD mRNA abundance, the enzyme involved with stability 
of HIF-1α stability and whose activity is regulated by hypoxia, was tested.  Following treatment 
with vehicle or 1,25(OH)2D, the PHD mRNA abundance was significantly reduced only under 





Figure 2: The effects of 1,25(OH)2D on the expression of 
PHD mRNA expression under normal and hypoxic 
conditions. Cells were treated for 24 hours with vehicle of 
1,25(OH)2D, and cells harvested for determination of HIF-1α 
mRNA abundance using RT-PCR.  Bars with different letters 

















To determine if the changes in the HIF-1α protein expression affected the downstream 
activity of this transcriptional factor, the effect of 1,25(OH)2D treatment of a well described 
transcriptional target of HIF-1α, vascular endothelial growth factor (VEGF), was tested.   
Treatment with 1,25(OH)2D reduced VEGF mRNA expression only under normoxic conditions 











Figure 3: The effects of 1,25(OH)2D on the expression of 
VEGF mRNA under normal and hypoxic conditions. 
Cells were treated for 24 hours with vehicle of 
1,25(OH)2D, and cells harvested for determination of 
HIF-1α mRNA abundance using RT-PCR.  Bars with 
different letters indicate significant difference.  
 












 Hypoxia in the untransformed LXSN cells increased VEGF, reduced HIF-1α and did not 
change PHD mRNA expression. Hypoxia in the ErbB2-containing cells lead to no change in 
VEGF and a reduction in PHD, but a similar reduction in HIF-1α mRNA expression as in 
LXSN cells. In both the untransformed and the ErbB2-containing cells, 1,25(OH)2D did not 
alter VEGF expression under hypoxic conditions. Under normoxic conditions, 1,25(OH)2D 
did not alter the expression of VEGF in untransformed cells, but VEGF expression in ErbB2 
cells was reduced. In contrast to the hypothesis, 1,25(OH)2D significantly reduced the 
expression of HIF-1α in the normoxic condition but there was no difference under hypoxic 
conditions, and the results were similar in the ErbB2-containing cells. There was no 
difference in PHD expression with 1,25(OH)2D treatment under both conditions in the 
untransformed cells.  However, under normoxic conditions, 1,25(OH)2D treatment reduced 
the expression of PHD in the ErbB2-containing cell line. These results suggest that HIF-1α is 
regulated similarly in the untransformed and ErbB2-containing cells under both normoxic 
and hypoxic conditions, but PHD regulation differs in the cell lines under normoxic 
conditions. 
 Thus, overall, 1,25(OH)2D treatment did not change mRNA abundance of any of the 
genes tested, HIF-1α, PHD or VEGF under hypoxic condition in either untransformed or 
ErbB2 containing cells.  Although 1,25(OH)2D treatment reduced HIF-1α mRNA abundance 
under normoxic conditions in untransformed cells, there was no effect on its target gene, 
VEGF mRNA.  In contrast, in ErbB2 containing cells, 1,25(OH)2D not only reduced mRNA 
abundance of HIF-1α but also of its target gene, VEGF.  These results are consistent with 
down regulation of HIF-1α by 1,25(OH)2D affecting the down regulation of VEGF.  In 
addition, 1,25(OH)2D treatment reduced PHD mRNA abundance.  If the decrease in PHD 
alters overall activity of this enzyme, this would lead to an increase in the stability of HIF-1α, 
which is not consistent with the decrease in VEGF mRNA. 
 Future studies are required to better understand the regulation of HIF-1α by 1,25(OH)2D.  
Cell culture studies should be done to explore the differential regulation of PHD in 
untransformed compared to ErbB2 containing cells. Other cell lines should be tested to see if 
these results will apply in other cancers. Animal studies should be completed on animals that 
have tumors containing the ErbB2 oncogene and those who don’t.  These studies would 
contribute to a better understanding of what may happen in humans.  Ultimately, this 
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